For US Healthcare Professionals

Next-Generation LDL-C Reduction,* FDA-Approved

A 3rd generation, small binding protein PCSK9i1,2

  • Robust, sustained LDL-C lowering1-3,*
  • Once-monthly, single, subcutaneous injection2
  • Self administration2
  • Room temperature storage for up to 3 months2,†

PCSK9i, proprotein convertase subtilisin/kexin type 9 inhibitor.

* Indicated as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH).

†Store refrigerated at 2°C to 8°C (36°F to 46°F). LEROCHOL may be kept at room temperature up to 25°C (77°F) in the original carton and must be used within 3 months of being removed from the refrigerator. If not used within 3 months, discard LEROCHOL.2

    References:
  1. Klug EQ, Llerena S, Burgess LJ, et al. Efficacy and safety of lerodalcibep in patients with or at high risk of cardiovascular disease: a randomized clinical trial. JAMA Cardiol. 2024;9(9):800-807.
  2. Lerochol [prescribing information]. LIB Therapeutics; 2025.
  3. Raal F, Fourie N, Scott R, et al. Long-term efficacy and safety of lerodalcibep in heterozygous familial hypercholesterolaemia: the LIBerate-HeFH trial. Eur Heart J. 2023;44(40):4272-4280.

IMPORTANT SAFETY INFORMATION

Adverse Reactions

  • The most commonly occurring adverse reactions in clinical trials in primary hyperlipidemia in adults (including heterozygous familial hypercholesterolemia [HeFH]) ≥2% of patients treated with LEROCHOL® (lerodalcibep-liga) and occurring more frequently than with placebo were nasopharyngitis (15% and 14% versus placebo), local injection site reactions (12% and 5% versus placebo) and peripheral edema (2% and <1% versus placebo).
  • The most commonly occurring adverse reactions in clinical trials in HeFH (≥2% of patients treated with LEROCHOL and occurring more frequently than with placebo) were injection site reactions (18% and 3% versus placebo), nasopharyngitis (13% and 9% versus placebo), diarrhea (3% and 1% versus placebo), nausea (2% and 0% versus placebo) and peripheral edema (2% and <1% versus placebo).
  • The most frequent adverse reaction leading to treatment discontinuation in trials in primary hypercholesterolemia in adults was injection site reactions, with a higher frequency in the LEROCHOL-treated group compared to placebo-treated patients (1% versus 0%).

Immunogenicity

  • LEROCHOL is a recombinant fusion protein. As with all therapeutic proteins, there is potential for immunogenicity with LEROCHOL.

INDICATIONS

LEROCHOL® (lerodalcibep-liga) is indicated as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH).

Please see full Prescribing Information.